Skip to main content
Premium Trial:

Request an Annual Quote

Stopped It

Outside experts have criticized the recent decision by the US Food and Drug Administration to stop an effort aimed at halting the spread of SARS-CoV-2 in the Seattle area, Stat News reports.

In early March, the Bill & Melinda Gates Foundation announced that it was going to fund home SARS-CoV-2 testing kits for Seattle. This effort, dubbed the Seattle Coronavirus Assessment Network, grew out of the Seattle Flu Study at the University of Washington that was tracking the spread of influenza, but changed gears to focus on the coronavirus, as the Seattle Times then noted.

But the New York Times reported earlier this month that the project, which was sending those testing kits to both healthy and sick people and had been operating with state approval, was informed it needed the OK from federal officials as well. In particular, the agency tells Stat News that the project didn't have the needed Emergency Use Authorization or institutional review board approval. Stat News adds that the project appears to have misinterpreted the FDA guidance on home testing, which had shifted throughout the early stages of the pandemic.

Still, experts tell it that the agency's move to shut the program down wasn't necessary, as it could have instructed SCAN to re-apply for ethics approval. "The FDA's position here is untenable," Eric Topol, director of the Scripps Research Translational Institute, which also has a coronavirus tracking effort, tells it. "If they really wanted to foster progress rather than take down our best academic effort to study this virus, that's what they would do."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.